98%
921
2 minutes
20
Pharmacokinetic issues were the leading cause of drug attrition, accounting for approximately 40% of all cases before the turn of the century. To this end, several high-throughput in vitro assays like microsomal stability have been developed to evaluate the pharmacokinetic profiles of compounds in the early stages of drug discovery. At NCATS, a single-point rat liver microsomal (RLM) stability assay is used as a Tier I assay, while human liver microsomal (HLM) stability is employed as a Tier II assay. We experimentally screened and collected data on over 30,000 compounds for RLM stability and over 7000 compounds for HLM stability. Although HLM stability screening provides valuable insights, the increasing number of hits generated, along with the time- and resource-intensive nature of the assay, highlights the need for alternative strategies. One promising approach is leveraging in silico models trained on these experimental datasets. We describe the development of an HLM stability prediction model using our in-house HLM stability dataset. Employing both classical machine learning methods and advanced techniques, such as neural networks, we achieved model accuracies exceeding 80%. Moreover, we validated our model using external test sets and found that our models are comparable to some of the best models in literature. Additionally, the strong correlation observed between our RLM and HLM data was further reinforced by the fact that our HLM model performance improved when using RLM stability predictions as an input descriptor. The best model along with a subset of our dataset (PubChem AID: 1963597) has been made publicly accessible on the ADME@NCATS website for the benefit of the greater drug discovery community. To the best of our knowledge, it is the largest open-source model of its kind and the first to leverage cross-species data.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11510424 | PMC |
http://dx.doi.org/10.3390/pharmaceutics16101257 | DOI Listing |
J Cheminform
September 2025
College of Pharmacy, Chung-Ang University, Seoul, 06974, Republic of Korea.
The metabolic stability of a drug is a crucial determinant of its pharmacokinetic properties, including clearance, half-life, and oral bioavailability. Accurate predictions of metabolic stability can significantly streamline the drug discovery process. In this study, we present MetaboGNN, an advanced model for predicting liver metabolic stability based on Graph Neural Networks (GNNs) and Graph Contrastive Learning (GCL).
View Article and Find Full Text PDFJ Pharm Biomed Anal
August 2025
Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research, Sector 67, S.A.S. Nagar, Mohali, Punjab 160062, India. Electronic address:
Small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonists are emerging as promising therapeutic agents for type 2 diabetes mellitus (T2DM) and obesity. Danuglipron, a novel investigational GLP-1R agonist, has demonstrated notable efficacy in clinical trials. This study aimed to evaluate the in vitro metabolic stability of danuglipron and to identify its metabolites both in vitro and in vivo.
View Article and Find Full Text PDFAnal Methods
July 2025
Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.
Fedratinib (INREBIC®; FDB), an orally administered selective Janus kinase 2 (JAK-2) inhibitor, has been approved by the FDA for the treatment of intermediate-2 or high-risk primary or secondary myelofibrosis in adult patients. This study established a sensitive, fast, green, and dependable UPLC-MS/MS approach for quantifying FDB in human liver microsomes (HLMs); moreover, this approach was employed to assess the metabolic stability of FDB in HLMs. The validation steps of the UPLC-MS/MS approach adhered to the US-FDA principles for bioanalytical method validation.
View Article and Find Full Text PDFEur J Med Chem
October 2025
Key Laboratory of Drug Targeting and Drug Delivery System of Ministry of Education, West China School of Pharmacy, Sichuan University, Sichuan, 610041, China. Electronic address:
Inflammatory programmed cell death mediated by NLRP3 inflammasome activation is one of the most representative forms of pyroptosis, involving multiple autoinflammatory diseases. In this investigation, we report the discovery of 3-pyridazinesulfonyl derivatives as a new class of inhibitors against NLRP3 inflammasome-dependent pyroptosis. We initially performed a phenotypic screening against NLRP3-dependent pyroptosis and discovered compound 1 (Hit-1), which showed moderate anti-pyroptotic activity (EC = 10.
View Article and Find Full Text PDFBMC Prim Care
May 2025
School of Public Health, Capital Medical University, No. 10, Xitoutiao, Youanmenwai Street, Fengtai District, Beijing, 10069, China.
Background: The high turnover intentions among family doctos (FDs) in China have impacted the stability of teams and the quality of healthcare services in community health centers (CHCs). The factors influencing FDs' turnover intentions include not only individual characteristics but also organizational environmental factors within CHCs. This study aims to explore the mechanism of the impact of FDs' professional identification and organizational incentives on their turnover intentions.
View Article and Find Full Text PDF